Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Both inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) have contributed to the rapid disappearance of paralytic poliomyelitis from developed countries despite possessing different vaccine properties. Due to cost, ease of use, and other properties, the Expanded Programme on Immunization added OPV to the routine infant immunization schedule for low-income countries in 1974, but variable vaccine uptake and impaired immune responses due to poor sanitation limited the impact. Following launch of the Global Polio Eradication Initiative in 1988, poliomyelitis incidence has been reduced by >99% and types 2 and 3 wild polioviruses are now eradicated, but progress against type 1 polioviruses which are now confined to Afghanistan and Pakistan has slowed due to insecurity, poor access, and other problems. A strategic, globally coordinated replacement of trivalent OPV with bivalent 1, 3 OPV in 2016 reduced the incidence of vaccine-associated paralytic poliomyelitis (VAPP) but allowed the escape of type 2 vaccine–derived polioviruses (VDPV2) in areas with low immunization rates and use of monovalent OPV2 in response seeded new VDPV2 outbreaks and reestablishment of type 2 endemicity. A novel, more genetically stable type 2 OPV vaccine is undergoing clinical evaluation and may soon be deployed prevent or reduce VDPV2 emergences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A new IPV has been licensed in Denmark and will soon be available on the global market. This vaccine contains an alum adjuvant and has only one-tenth of the antigen content of the conventional IPV [112].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Self-citationFactors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Platt, L. R., Estivariz, C. F., & Sutter, R. W. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu184 · Cited by 267
Self-citationEngineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citationGlobal eradication of poliomyelitis by the year 2000.
(1988) · PubMed · Cited by 147
Sutter, R. W., John, T. J., Jain, H., Agarkhedkar, S., Ramanan, P. V., Verma, H., Deshpande, J. M., Singh, A. P., Sreevatsava, M., Malankar, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61230-5 · Cited by 144
Self-citationVan Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Self-citationMacklin, G. R., O’Reilly, K. M., Grassly, N. C., Edmunds, W. J., Mach, O., Santhana Gopala Krishnan, R., Voorman, A., Vertefeuille, J. F., Abdelwahab, J., Gumede, N., et al. (2020) · Science · doi:10.1126/science.aba1238 · Cited by 141
Self-citationCáceres, V. M., & Sutter, R. W. (2001) · Clinical Infectious Diseases · doi:10.1086/321905 · Cited by 112
Self-citationParalytic Disease Associated With Oral Polio Vaccines
Henderson, D. A., Witte, J. J., Morris, L., & Langmuir, A. D. (1964) · JAMA · doi:10.1001/jama.1964.03070140047006 · Cited by 108
Cited by
A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story
Bandyopadhyay, A. S., & Zipursky, S. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00582-5 · Cited by 55
Self-citationda Silva, T. M. R., de Sá, A. C. M. G. N., Prates, E. J. S., Saldanha, R. D. F., da Silva, T. P. R., Teixeira, A. M. D. S., Beinner, M. A., de Oliveira, S. R., de Sá, A. T. N., Matozinhos, F. P., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16192-8 · Cited by 39
Kumar, P., Bird, C., Holland, D. A., Joshi, S. B., & Volkin, D. B. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2154100 · Cited by 36
The Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
“This vaccine contains an alum adjuvant and has only one-tenth of the antigen content of the conventional IPV [112].”
BackgroundStrategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases
Feng, F., Wen, Z., Chen, J., Yuan, Y., Wang, C., & Sun, C. (2022) · Viruses · doi:10.3390/v14030520 · Cited by 31
Metadata
- Authors
- Modlin, J. F., Bandyopadhyay, A. S., & Sutter, R.
- Affiliations
- Dartmouth College (US)
- Gates Foundation (US)
- World Health Organization (CH)
- Corresponding author
- Modlin, John F
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-09-30
- Volume
- 224
- Issue
- Supplement_4
- Pages
- S398-S404
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC8482017
- OpenAlex
- W3202605976
- Cited by
- 49
- References
- 16
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 14 · 2023: 10 · 2022: 14
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Infectious Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bill and Melinda Gates Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- poliomyelitis, polio vaccine, inactivated poliovirus vaccine, oral polio vaccine, Expanded Programme on Immunization, Global Polio Eradication Initiative, vaccine-derived poliovirus type 2, vaccine-associated paralytic poliomyelitis, vaccine escape, vaccination coverage, sanitation, Afghanistan, Pakistan
- MeSH terms
- Humans, Immunization Schedule, Infant, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination, Global Health, Immunization Programs, Poliovirus, Poliovirus Vaccines, Disease Eradication
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication. https://app.cochat.ai/papers/10.1093/infdis/jiaa622
- The paper
- Modlin, J. F., Bandyopadhyay, A. S., & Sutter, R. (2021). Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaa622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.